verapamil has been researched along with B-Cell Leukemia in 1 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Vervoordeldonk, SF | 1 |
Balkenende, AY | 1 |
van den Berg, H | 1 |
von dem Borne, AE | 1 |
van der Schoot, CE | 1 |
Van Leeuwen, EF | 1 |
Slaper-Cortenbach, IC | 1 |
1 other study available for verapamil and B-Cell Leukemia
Article | Year |
---|---|
Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, CD19; Antigens, Differentiation, B-Lymphocy | 1996 |